A controlled trial of anti-tumor necrosis factor alpha antibody for Crohn's disease
References (0)
Cited by (14)
The role of anticytokine therapy in heart failure: Recent lessons from preclinical and clinical trials?
2003, Medical Clinics of North AmericaIntegrating anti-tumor necrosis factor therapy in inflammatory bowel disease: Current and future perspectives
2001, American Journal of GastroenterologyCitation Excerpt :The mean CDAI scores did not differ significantly in placebo and infliximab-treated patients at 8 wk. Stated in more conventional terms, approximately 30% of infliximab-treated patients were in clinical remission (p = 0.074 by Fisher’s exact test, as compared with placebo patients) and 50% of infliximab-treated patients had a clinical response (decrease in CDAI of ≥70 points) by 2 wk after infusion (79). These results are comparable to those described for pooled-dose remission (27–42%) or response (61–68%) rates at 2 wk after infusion in the major efficacy trials of infliximab (Table 1).
The role of tumor necrosis factor in the pathophysiology of heart failure
2000, Journal of the American College of CardiologyCitation Excerpt :By contrast, excessive activation of TNF alpha or nontissue specific expression leads to tissue necrosis and apoptosis. Indeed, recent studies have demonstrated a causative role for TNF alpha in a group of diseases including: septic shock, rheumatoid arthritis (26), preeclampsia (27), hemolytic uremic syndrome (28), allograft rejection (29)and regional enteritis (30). The first recognition that TNF alpha might participate in the development of congestive heart failure (CHF) came in 1990 when Levine et al. (31)demonstrated that circulating levels of TNF alpha were elevated in patients with end stage heart failure and cachexia.
CD4<sup>+</sup> T-cells in the regulation of inflammatory responses in the intestine
1997, Research in ImmunologyTherapeutic effects of roxithromycin in interleukin-10-deficient colitis
2007, Inflammatory Bowel Diseases